Targeting hypoxic tumor cell viability with carbohydrate-based carbonic anhydrase IX and XII inhibitors.
Morris JC, Chiche J, Grellier C, Lopez M, Bornaghi LF, Maresca A, Supuran CT, Pouysségur J, Poulsen SA
You May Also Be Interested In:
BSC Technical Training | Baker Company | Oct 19-21, 2026
Read more
Baker Flow Werkbanken – Kwaliteit die blijft presteren
Read more
Baker Hosts International Dealer Meeting & Factory Visit in Bridgend, Wales
Read more
First EuroFlow EF-N Installed in the U.S. at University of Miami Sylvester Comprehensive Cancer Center
Read more
Cold Lab Services and The Baker Company: A Strong New Partnership
Read more
Lifecycle Support Update 2026: Baker and/or CleanAir Benelux Flowbenches
Read more
The Baker Company certified ISO 14001:2015 for 2026
Read more
How Hypoxia Rewires Epigenetics and Splicing to Drive EMT in Breast Cancer
Read more
What Oxygen Really Means for Extracellular Vesicles
Read more
Stay informed
Subscribe to the Baker Company newsletter for the latest articles, product updates, and event announcements.
Stay up to date